Some of the highlights from the October issue include:
- Marking the 10th International Brain Tumour Awareness Week, which took ran from Saturday, 22nd October to Saturday, 29th October inclusive. An incredible range of activities took place across the world (click here for a summary of some). For more information on how to get involved in this year's “World Walk”, please click here.
- The White House (USA) has released two Cancer Moonshot reports that give a blueprint for the future of the initiative that aims to rapidly advance cancer research.
- Findings from a randomised phase 3 trial have shown no difference in health-related quality of life (HRQOL) between temozolomide or radiotherapy treatment in patients with high risk low-grade glioma, raising questions about the convention of choosing temozolomide over radiotherapy in this patient group.
- According to a trial in 54 paediatric patients with progressive or inoperable low-grade glioma, the chemotherapy drug vinblastine is as effective as other first-line treatments. The authors suggest it could be used as an affordable treatment option in low-income countries.
- A series of mouse experiments have revealed that glioblastoma cells rely on a supply of cholesterol to survive and grow. Testing of a candidate drug called LXR-623 that disrupts the cholesterol import caused cell death and shrinkage in glioblastoma tumours.
- In a phase I/II clinical trial, 72% of paediatric patients with BRAF V600 mutation-positive low-grade glioma have shown a response to dabrafenib, a drug that specifically targets cancers with this mutation. 15-20% of paediatric low-grade glioma tumours have this mutation, which is associated with poorer survival.
- Fans of the Canadian band Tragically Hip have donated over CA$1 million toward brain tumour research since the group's final tour ended on 20 August. The lead singer of the group, Gord Downie, announced that he had been diagnosed with a “terminal” brain tumour on 24 May 2016.
- The UK-based charity Brain Tumour Research has published their latest “National Research Funding Report 2016”, which continues to highlight that brain tumour research in the UK is “drastically underfunded”. It calls upon the UK Government to urgently address a range of substantial shortcomings.
- You can read the IBTA e-News October edition in full online here. You can sign up to receive the e-News every month by registering here.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences.
To see an archive of existing e-News issues, click here.